Chemistry:JP-2266

From HandWiki
Revision as of 02:12, 6 February 2024 by SpringEdit (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

JP-2266[1] is a small-molecule SGLT1/2 dual inhibitor that is designed to help patients with diabetes. It was tested as an adjunct to insulin in type 1 diabetes[2] and also in patients with type 2 diabetes.[3] It is reported to be a better drug candidate than sotagliflozin.[4]

References

  1. ↑ "JP 2266 - AdisInsight". https://adisinsight.springer.com/drugs/800044959. 
  2. ↑ Park, Youngjun (1 July 2018). "Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes" (in en). Diabetes 67 (Supplement_1). doi:10.2337/db18-2303-PUB. ISSN 0012-1797. 
  3. ↑ "Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients". https://clinicaltrials.gov/study/NCT06144788?aggFilters=phase:2%203,status:not%20rec%20act&rank=7. 
  4. ↑ "Jeil’s development of diabetes treatment goes as planned" (in en). KBR. 25 June 2018. https://www.koreabiomed.com/news/articleView.html?idxno=3572. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:JP-2266&oldid=3332001"